LOGIN  |  REGISTER
Terns Pharmaceuticals

NeuroOne® Medical to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14

February 09, 2023 | Last Trade: US$0.83 0.08 -8.33

EDEN PRAIRIE, Minn., Feb. 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time.

Conference Call and Webcast Information:

Tuesday, February 14, 20234:30 PM Eastern Time

Participant Dial-In:
877-405-1216 / 201-689-8336

Live Webcast: 
Join here

Phone Replay:
877-660-6853 / 201-612-7415, Access ID: 13736384; available through February 28, 2023

Webcast Replay:       
Available for 12 months

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.  For more information, visit nmtc1.com

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB